Antimicrobial De-Escalation in Critically Ill Patients.

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Antimicrobial Stewardship

Background:

• Antimicrobial de-escalation (ADE) involves stopping or narrowing antimicrobial therapy.
• It's a key strategy in antimicrobial stewardship (AMS).
• Its safety and effectiveness in critically ill patients require comprehensive review.

Purpose of the Study:

• To review the literature on the effectiveness and safety of ADE in critically ill patients.
• To focus on special conditions like antifungal therapy and high-risk patient categories.
• To evaluate the impact of ADE on antimicrobial resistance and treatment duration.

Main Methods:

• Literature review of existing studies on antimicrobial de-escalation.
• Analysis of data concerning critically ill patients, special conditions, and high-risk categories.
• Examination of microbiological documentation's role in ADE implementation.

Main Results:

• ADE is generally considered safe in critically ill patients with infections, provided high-quality microbiological sampling.
• No definitive assessment exists regarding ADE's effect on resistance development.
• Concerns exist about prolonged antibiotic treatment as a potential side effect in high-risk groups (e.g., neutropenic patients, IAIs).

Conclusions:

• Antimicrobial de-escalation can be safely implemented in critically ill patients with adequate microbiological support.
• Further studies are necessary to clarify ADE's applicability in specific populations and its impact on resistance.
• Accelerating pathogen identification through new diagnostic tools is crucial for increasing ADE rates.